What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Side effects
Page 20 of 21 of this archive, newest first.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
What the cagrilintide schedule assumes about a person it has never met
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.
The arithmetic of a step: what doubling a dose actually asks of you
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Turkey guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dose-limiting: a definition worth being strict about
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
Target dose, effective dose, and the distance between them
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
Stepping down is part of titration
The practice is near-universal, clinically sensible, and supported by observational data rather than randomised comparison. We say which is which.
What the new Argentina guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Sweden pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Italy pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The eighteenth month, and the conversation that should have happened in the third
Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.
South Africa pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Italy guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Forty-four per cent: reading the nausea figure properly
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Attribution is the hard part
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Background rates, and why they matter for attribution
The features that should prompt urgent assessment, stated once and plainly.